378 related articles for article (PubMed ID: 28427515)
21. Targeting fibroblast growth factor receptor in breast cancer: a promise or a pitfall?
Bedussi F; Bottini A; Memo M; Fox SB; Sigala S; Generali D
Expert Opin Ther Targets; 2014 Jun; 18(6):665-78. PubMed ID: 24833241
[TBL] [Abstract][Full Text] [Related]
22. Fibroblast growth factor signaling and inhibition in non-small cell lung cancer and their role in squamous cell tumors.
Salgia R
Cancer Med; 2014 Jun; 3(3):681-92. PubMed ID: 24711160
[TBL] [Abstract][Full Text] [Related]
23. Targeting FGFR pathway in breast cancer.
Perez-Garcia J; Muñoz-Couselo E; Soberino J; Racca F; Cortes J
Breast; 2018 Feb; 37():126-133. PubMed ID: 29156384
[TBL] [Abstract][Full Text] [Related]
24. FGFR-targeted therapeutics for the treatment of breast cancer.
De Luca A; Frezzetti D; Gallo M; Normanno N
Expert Opin Investig Drugs; 2017 Mar; 26(3):303-311. PubMed ID: 28121208
[TBL] [Abstract][Full Text] [Related]
25. Implications of Fibroblast Growth Factors (FGFs) in Cancer: From Prognostic to Therapeutic Applications.
Dianat-Moghadam H; Teimoori-Toolabi L
Curr Drug Targets; 2019; 20(8):852-870. PubMed ID: 30648505
[TBL] [Abstract][Full Text] [Related]
26. Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy.
Biello F; Burrafato G; Rijavec E; Genova C; Barletta G; Truini A; Coco S; Bello MG; Alama A; Boccardo F; Grossi F
Anticancer Agents Med Chem; 2016; 16(9):1142-54. PubMed ID: 26845137
[TBL] [Abstract][Full Text] [Related]
27. Fibroblast growth factor receptor signaling in hereditary and neoplastic disease: biologic and clinical implications.
Helsten T; Schwaederle M; Kurzrock R
Cancer Metastasis Rev; 2015 Sep; 34(3):479-96. PubMed ID: 26224133
[TBL] [Abstract][Full Text] [Related]
28. The FGF/FGFR signalling mediated anti-cancer drug resistance and therapeutic intervention.
Mahapatra S; Jonniya NA; Koirala S; Ursal KD; Kar P
J Biomol Struct Dyn; 2023; 41(22):13509-13533. PubMed ID: 36995019
[TBL] [Abstract][Full Text] [Related]
29. Targeting FGFR Signaling in Cancer.
Touat M; Ileana E; Postel-Vinay S; André F; Soria JC
Clin Cancer Res; 2015 Jun; 21(12):2684-94. PubMed ID: 26078430
[TBL] [Abstract][Full Text] [Related]
30. The role of fibroblast growth factors in tumor growth.
Korc M; Friesel RE
Curr Cancer Drug Targets; 2009 Aug; 9(5):639-51. PubMed ID: 19508171
[TBL] [Abstract][Full Text] [Related]
31. Fibroblast Growth Factor Receptors (FGFRs): Structures and Small Molecule Inhibitors.
Dai S; Zhou Z; Chen Z; Xu G; Chen Y
Cells; 2019 Jun; 8(6):. PubMed ID: 31216761
[TBL] [Abstract][Full Text] [Related]
32. Fibroblast growth factor receptor inhibitors: patent review (2015-2019).
Marseglia G; Lodola A; Mor M; Castelli R
Expert Opin Ther Pat; 2019 Dec; 29(12):965-977. PubMed ID: 31679402
[No Abstract] [Full Text] [Related]
33. Recent advances of dual FGFR inhibitors as a novel therapy for cancer.
Liang Q; Wang J; Zhao L; Hou J; Hu Y; Shi J
Eur J Med Chem; 2021 Mar; 214():113205. PubMed ID: 33556787
[TBL] [Abstract][Full Text] [Related]
34. FGFR signaling and endocrine resistance in breast cancer: Challenges for the clinical development of FGFR inhibitors.
Servetto A; Formisano L; Arteaga CL
Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188595. PubMed ID: 34303787
[TBL] [Abstract][Full Text] [Related]
35. Fibroblast growth factor (FGF), FGF receptor (FGFR), and cyclin D1 (CCND1) DNA methylation in head and neck squamous cell carcinomas is associated with transcriptional activity, gene amplification, human papillomavirus (HPV) status, and sensitivity to tyrosine kinase inhibitors.
Bao Y; Gabrielpillai J; Dietrich J; Zarbl R; Strieth S; Schröck F; Dietrich D
Clin Epigenetics; 2021 Dec; 13(1):228. PubMed ID: 34933671
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of the FGF/FGFR System Induces Apoptosis in Lung Cancer Cells via c-Myc Downregulation and Oxidative Stress.
Giacomini A; Taranto S; Rezzola S; Matarazzo S; Grillo E; Bugatti M; Scotuzzi A; Guerra J; Di Trani M; Presta M; Ronca R
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33317057
[TBL] [Abstract][Full Text] [Related]
37. Tumour cell responses to new fibroblast growth factor receptor tyrosine kinase inhibitors and identification of a gatekeeper mutation in FGFR3 as a mechanism of acquired resistance.
Chell V; Balmanno K; Little AS; Wilson M; Andrews S; Blockley L; Hampson M; Gavine PR; Cook SJ
Oncogene; 2013 Jun; 32(25):3059-70. PubMed ID: 22869148
[TBL] [Abstract][Full Text] [Related]
38. Blocking the FGF/FGFR system as a "two-compartment" antiangiogenic/antitumor approach in cancer therapy.
Giacomini A; Chiodelli P; Matarazzo S; Rusnati M; Presta M; Ronca R
Pharmacol Res; 2016 May; 107():172-185. PubMed ID: 27013279
[TBL] [Abstract][Full Text] [Related]
39. Fibroblast growth factor receptors as treatment targets in clinical oncology.
Katoh M
Nat Rev Clin Oncol; 2019 Feb; 16(2):105-122. PubMed ID: 30367139
[TBL] [Abstract][Full Text] [Related]
40. De-regulated FGF receptors as therapeutic targets in cancer.
Knights V; Cook SJ
Pharmacol Ther; 2010 Jan; 125(1):105-17. PubMed ID: 19874848
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
